

Supplementary Documents [IFRS]

Financial results for the first six months of the fiscal year 2024 (FY2024)

Astellas Pharma Inc.

- Q2 YTD/FY2024 Financial Results
 - Six months ended September 30, 2024
 - Three months ended September 30, 2024
- Pipeline list

Cautionary Notes

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties. Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

[Six months ended September 30, 2024]

1. Consolidated Results (Full Basis)

Unit: B¥

	Unit: B¥				FY23 Full Year	Initial Forecasts		Revised Forecasts		Change from FY23
	FY23 APR. - SEP.	FY24 APR. - SEP.	Change	Change (%)		FY24 Full Year	FY24 Full Year	Change (%)		
Revenue	767.1	935.6	168.5	22.0%	1,603.7	1,650.0	1,800.0	12.2%		
Cost of sales	143.4	173.8	30.5	21.3%	292.5	326.0	336.0	14.9%		
Ratio to Revenue	18.7%	18.6%			18.2%	19.8%	18.7%			
Gross profit	623.8	761.8	138.0	22.1%	1,311.2	1,324.0	1,464.0	11.7%		
SG&A expenses	347.5	406.4	58.9	17.0%	740.1	757.0	823.0	11.2%		
Ratio to Revenue	45.3%	43.4%			46.2%	45.9%	45.7%			
XTANDI co-promotion fee in the United States	93.0	126.0	33.0	35.5%	194.9	189.0	229.0	17.5%		
SG&A excl. the above	254.4	280.4	26.0	10.2%	545.2	568.0	594.0	8.9%		
Ratio to Revenue	33.2%	30.0%			34.0%	34.4%	33.0%			
R&D expenses	141.9	172.3	30.4	21.4%	294.2	317.0	341.0	15.9%		
Ratio to Revenue	18.5%	18.4%			18.3%	19.2%	18.9%			
Amortisation of intangible assets	33.7	69.2	35.5	105.2%	98.8					
Gain on divestiture of intangible assets	9.4	0.9	-8.5	-90.3%	9.7					
Share of profit (loss) of investments accounted for using equity method	-0.2	1.4	1.7	-	-3.2					
Other income	7.1	4.5	-2.6	-36.9%	8.7					
Fair value remeasurements on contingent consideration	2.6	2.6	0.0	1.9%	2.6					
Other expenses	61.7	26.9	-34.8	-56.4%	167.8					
Impairment losses	13.2	0.7	-12.5	-95.0%	78.9					
Restructuring costs	2.8	7.9	5.1	181.9%	25.4					
Net foreign exchange losses	0.7	12.2	11.5	-	0.8					
Fair value remeasurements on contingent consideration	11.3	0.7	-10.7	-94.2%	24.7					
Replacement awards with business combination*	32.6	-	-32.6	-	33.4					
Operating profit	55.2	93.7	38.6	69.9%	25.5	48.0	80.0	213.5%		
Ratio to Revenue	7.2%	10.0%			1.6%	2.9%	4.4%			
Finance income	6.2	4.9	-1.3	-20.8%	11.5					
Finance expenses	5.0	9.5	4.6	91.3%	12.0					
Profit before tax	56.3	89.0	32.7	58.1%	25.0	43.0	70.0	180.3%		
Ratio to Revenue	7.3%	9.5%			1.6%	2.6%	3.9%			
Income tax expense	20.5	15.5	-5.0	-24.3%	7.9					
Profit	35.8	73.5	37.7	105.3%	17.0	30.0	50.0	193.3%		
Ratio to Revenue	4.7%	7.9%			1.1%	1.8%	2.8%			
Comprehensive income	192.7	1.4	-191.3	-99.3%	205.6					

(*) Payment for Iveric Bio's unvested share-based payments, such as share options

2. Consolidated Results (Core Basis)

Unit: B¥

	FY23 APR. - SEP.	FY24 APR. - SEP.	Change	Change (%)
Revenue	767.1	935.6	168.5	22.0%
Cost of sales	143.4	173.8	30.5	21.3%
Ratio to Revenue	18.7%	18.6%		
Gross profit	623.8	761.8	138.0	22.1%
SG&A expenses	347.5	406.4	58.9	17.0%
Ratio to Revenue	45.3%	43.4%		
XTANDI co-promotion fee in the United States	93.0	126.0	33.0	35.5%
SG&A excl. the above	254.4	280.4	26.0	10.2%
Ratio to Revenue	33.2%	30.0%		
R&D expenses	141.9	172.3	30.4	21.4%
Ratio to Revenue	18.5%	18.4%		
Operating profit	134.4	183.1	48.7	36.2%
Ratio to Revenue	17.5%	19.6%		
Finance income	6.2	4.9	-1.3	-20.8%
Finance expenses	5.0	9.5	4.6	91.3%
Profit before tax	135.5	178.4	42.9	31.6%
Ratio to Revenue	17.7%	19.1%		
Income tax expense	26.3	37.6	11.4	43.3%
Profit	109.3	140.8	31.5	28.8%
Ratio to Revenue	14.2%	15.0%		

	Initial Forecasts	Revised Forecasts	Change from FY23
	FY24 Full Year	FY24 Full Year	Change (%)
FY23 Full Year	1,603.7		
	1,650.0	1,800.0	12.2%
	292.5	336.0	14.9%
	18.2%	18.7%	
	1,311.2	1,464.0	11.7%
	740.1	823.0	11.2%
	46.2%	45.7%	
	194.9	229.0	17.5%
	545.2	594.0	8.9%
	34.0%	33.0%	
	294.2	317.0	15.9%
	18.3%	18.9%	
	276.9	300.0	8.3%
	17.3%	16.7%	
	11.5		
	12.0		
	276.3		
	17.2%		
	53.1		
	223.2	220.0	-1.4%
	13.9%	12.2%	

3. Exchange Rate

Unit: yen

	FY23 APR. - SEP.Ave.	FY24 APR. - SEP.Ave.	FY23 End	FY24 Q2 End
USD/Yen	141	152	151	144
EUR/Yen	153	166	163	160

	Initial Forecasts	Revised Forecasts
	FY24 Full Year	FY24 Full Year
FY23 Full Year	145	
	145	149
	155	160

* Fx impacts: Revenue +54.8 billion yen and Core operating profit +13.7 billion yen

4. Reconciliation of Full Basis to Core Basis

Unit: B¥

	FY23 APR. - SEP.			FY24 APR. - SEP.		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Revenue	767.1	-	767.1	935.6	-	935.6
Cost of sales	143.4	-	143.4	173.8	-	173.8
Gross profit	623.8	-	623.8	761.8	-	761.8
SG&A expenses	347.5	-	347.5	406.4	-	406.4
R&D expenses	141.9	-	141.9	172.3	-	172.3
Amortisation of intangible assets *	33.7	-33.7	-	69.2	-69.2	-
Gain on divestiture of intangible assets *	9.4	-9.4	-	0.9	-0.9	-
Share of profit (loss) of investments accounted for using equity method *	-0.2	0.2	-	1.4	-1.4	-
Other income *	7.1	-7.1	-	4.5	-4.5	-
Other expenses *	61.7	-61.7	-	26.9	-26.9	-
Operating profit	55.2	79.2	134.4	93.7	89.3	183.1
Finance income	6.2	-	6.2	4.9	-	4.9
Finance expenses	5.0	-	5.0	9.5	-	9.5
Profit before tax	56.3	79.2	135.5	89.0	89.3	178.4
Income tax expense	20.5	5.7	26.3	15.5	22.1	37.6
Profit	35.8	73.5	109.3	73.5	67.2	140.8

* The definition of core-basis was changed from Q1/FY2024. In addition to the old definition's adjustments, 'Amortisation of intangible assets', 'Gain on divestiture of intangible assets' and 'Share of profit (loss) of investments accounted for using equity method' were newly excluded as new adjustment items. All figures above reflect this change.

"Other income" and "Other expenses" include gain/loss on sale and disposal of property, plant and equipment, impairment losses, restructuring costs, litigation costs and foreign exchange gains/losses, etc.

5. Revenue by Region

Unit: B¥

		FY23 APR. - SEP.	FY24 APR. - SEP.	Change	Change (%)
Revenue		767.1	935.6	168.5	22.0%
	Japan	137.6	133.5	-4.1	-3.0%
	Ratio to Revenue	17.9%	14.3%		
	United States	306.7	419.3	112.6	36.7%
	Ratio to Revenue	40.0%	44.8%		
	Established Markets	199.1	240.0	40.9	20.5%
	Ratio to Revenue	26.0%	25.7%		
	China	36.4	37.7	1.3	3.6%
	Ratio to Revenue	4.7%	4.0%		
	International Markets	83.2	100.0	16.8	20.2%
	Ratio to Revenue	10.8%	10.7%		
	Others	4.2	5.1	1.0	23.5%
	Ratio to Revenue	0.5%	0.5%		

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

	Initial Forecasts		Revised Forecasts		Change from FY23
	FY24 Full Year	FY24 Full Year	FY24 Full Year	FY24 Full Year	Change (%)
FY23 Full Year	1,603.7	1,650.0	1,800.0		12.2%
	270.1	278.7	270.1		0.0%
	16.8%	16.9%	15.0%		
	663.1	670.0	788.1		18.8%
	41.3%	40.6%	43.8%		
	415.6	437.4	470.0		13.1%
	25.9%	26.5%	26.1%		
	70.6	70.5	75.5		6.9%
	4.4%	4.3%	4.2%		
	177.0	187.0	190.3		7.5%
	11.0%	11.3%	10.6%		
	7.3	6.5	6.0		-17.7%
	0.5%	0.4%	0.3%		

6. Per Share Information

	FY23 APR. - SEP.	FY24 APR. - SEP.
The number of shares issued (thousand)	1,809,663	1,809,663
Treasury Shares (thousand)	16,796	19,555
The number of shares issued after deducting Treasury Shares (thousand)	1,792,866	1,790,107
Earnings per share (yen)	19.97	41.06
Earnings per share (yen) core basis	60.93	78.62
Dividend per share (yen)	35	37

- The numbers of shares stated in the business report are presented by disregarding any number of shares less than the specified units.

	Initial Forecasts		Revised Forecasts	
	FY24 Full Year	FY24 Full Year	FY24 Full Year	FY24 Full Year
FY23 Full Year	1,809,663			
	16,561			
	1,793,101			
	9.51	16.73	27.93	
	124.46	103.73	122.90	
	70	74	74	

7. Investment in Property, Plant and Equipment

Depreciation/Amortisation

Unit: B¥

	FY23 APR. - SEP.	FY24 APR. - SEP.	Change	Change (%)
Investment in Property, Plant and Equipment	16.7	28.7	11.9	71.3%
Depreciation (PP&E)	20.3	22.3	1.9	9.5%
Amortisation of Intangible Assets (incl. software, etc.)	41.9	78.0	36.1	86.3%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

	Initial Forecasts		Revised Forecasts		Change from FY23
	FY24 Full Year	FY24 Full Year	FY24 Full Year	FY24 Full Year	Change (%)
FY23 Full Year	35.4	55.0	55.0		55.2%
	42.4	42.0	45.0		6.1%
	115.4	161.0	161.0		39.5%

8. Sales of major products

1) Global

Unit: B¥

	Unit: B¥				FY23 Full Year	Initial Forecasts FY24 Full Year	Revised Forecasts FY24 Full Year	Change from FY23 Change (%)
	FY23 APR. - SEP.	FY24 APR. - SEP.	Change	Change (%)				
XTANDI	360.9	451.7	90.7	25.1%	750.5	757.0	859.7	14.6%
Japan	28.8	28.8	-0.1	-0.2%	56.7	58.9	58.9	3.9%
United States	181.3	245.2	63.9	35.2%	379.7	369.1	447.1	17.8%
Established Markets	112.1	131.7	19.6	17.5%	231.6	236.4	258.9	11.8%
China	7.9	6.9	-1.0	-13.1%	12.2	14.7	15.1	24.3%
International Markets	30.8	39.2	8.4	27.2%	70.3	77.9	79.7	13.4%
PADCEV	32.7	75.4	42.7	130.5%	85.4	151.2	166.9	95.6%
Japan	4.4	4.9	0.6	13.1%	8.5	11.3	12.4	45.0%
United States	23.0	53.1	30.2	131.4%	60.7	107.5	114.0	87.9%
Established Markets	5.1	15.0	9.9	192.4%	14.7	28.2	32.2	118.0%
China	-	0.2	0.2	-	0.1	0.7	3.8	-
International Markets	0.2	2.1	1.9	762.3%	1.3	3.4	4.6	245.2%
IZERVAY	1.2	28.1	26.9	-	12.1	46.4	69.5	472.7%
United States	1.2	28.1	26.9	-	12.1	46.1	69.5	472.7%
VEOZAH	1.3	14.8	13.5	-	7.3	28.3	31.6	333.6%
United States	1.3	13.6	12.3	968.6%	7.2	25.8	28.0	290.7%
Established Markets	-	1.1	1.1	-	0.1	2.0	3.2	-
VYLOY	-	1.2	1.2	-	-	3.7	5.1	-
Japan	-	1.2	1.2	-	-	2.1	3.7	-
XOSPATA	26.3	34.8	8.5	32.3%	55.1	60.0	64.7	17.5%
Japan	2.3	2.4	0.1	6.3%	4.4	5.0	5.0	14.5%
United States	14.0	17.8	3.8	27.1%	28.6	29.2	32.3	13.2%
Established Markets	7.2	9.1	1.9	26.7%	15.2	16.8	17.9	17.9%
China	1.2	3.0	1.8	154.6%	3.1	3.5	4.3	39.1%
International Markets	1.7	2.5	0.8	49.0%	3.9	5.5	5.2	33.3%
BETANIS/MYRBETRIQ/BETMIGA	95.8	77.5	-18.3	-19.1%	198.1	118.0	137.8	-30.4%
Japan	14.1	12.5	-1.6	-11.6%	27.4	25.7	25.7	-6.1%
United States	48.7	24.3	-24.4	-50.1%	101.3	16.6	32.8	-67.6%
Established Markets	24.3	30.3	6.0	24.7%	51.3	57.1	60.0	17.1%
China	0.7	0.9	0.1	18.5%	1.6	1.2	1.4	-10.5%
International Markets	8.0	9.6	1.6	20.2%	16.6	17.4	17.9	7.6%
PROGRAF	100.0	103.9	3.9	3.9%	203.1	191.8	195.5	-3.8%
Japan	15.3	12.0	-3.3	-21.6%	29.5	25.3	24.1	-18.2%
United States	5.0	5.3	0.3	6.1%	10.0	10.1	10.3	3.0%
Established Markets	35.9	37.5	1.6	4.4%	73.8	69.6	72.1	-2.3%
China	21.7	21.9	0.2	0.8%	43.5	41.3	42.0	-3.3%
International Markets	22.1	27.3	5.2	23.3%	46.3	45.5	46.9	1.2%

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

- XTANDI (China): From Q1/FY2024, the distribution model was changed. Due to the timing of shipments following this change, the figures decreased year on year. (Direct comparison showed an increase year on year)

- PADCEV (United States): Co-promotion revenue from Pfizer

- VEOZAH: Approved as "VEOZA" in ex-US

2) Revenue by region

(1) Japan

Unit: B¥

	FY23 APR. - SEP.	FY24 APR. - SEP.	Change	Change (%)
Revenue	137.6	133.5	-4.1	-3.0%
XTANDI	28.8	28.8	-0.1	-0.2%
PADCEV	4.4	4.9	0.6	13.1%
VYLOY	-	1.2	1.2	-
XOSPATA	2.3	2.4	0.1	6.3%
EVRENZO	1.1	0.9	-0.2	-19.2%
BETANIS	14.1	12.5	-1.6	-11.6%
PROGRAF (Including GRACEPTOR)	15.3	12.0	-3.3	-21.6%
SUGLAT [Family]	14.4	13.5	-0.9	-6.3%
SUJANU	5.6	5.4	-0.3	-4.8%
BLINCYTO	5.0	6.5	1.5	29.8%
EVENITY	23.5	27.4	4.0	16.9%
CIMZIA	5.2	4.9	-0.3	-6.3%

FY23 Full Year
270.1
56.7
8.5
-
4.4
2.1
27.4
29.5
27.9
11.0
11.2
48.8
10.0

Initial Forecasts	Revised Forecasts	Change from FY23
FY24 Full Year	FY24 Full Year	Change (%)
278.7	270.1	0.0%
58.9	58.9	3.9%
11.3	12.4	45.0%
2.1	3.7	-
5.0	5.0	14.5%
1.7	1.8	-16.5%
25.7	25.7	-6.1%
25.3	24.1	-18.2%
27.3	27.3	-2.3%

(2) United States

Unit: M\$

	FY23 APR. - SEP.	FY24 APR. - SEP.	Change	Change (%)
Revenue	2,175	2,750	575	26.4%
XTANDI	1,286	1,608	322	25.1%
PADCEV	163	349	186	114.0%
IZERVAY	8	184	176	-
VEOZAH	9	89	80	888.2%
XOSPATA	99	117	17	17.6%
MYRBETRIQ	346	160	-186	-53.8%
PROGRAF	35	35	-1	-1.9%
CRESEMBA	125	147	23	18.1%

FY23 Full Year
4,587
2,627
420
84
50
198
701
69
259

Initial Forecasts	Revised Forecasts	Change from FY23
FY24 Full Year	FY24 Full Year	Change (%)
4,621	5,299	15.5%
2,545	3,006	14.5%
742	767	82.7%
318	467	456.7%
178	188	279.8%
201	217	10.0%
114	221	-68.5%
70	69	0.1%
310	306	18.2%

(3) Established Markets

Unit: M€

	FY23 APR. - SEP.	FY24 APR. - SEP.	Change	Change (%)
Revenue	1,298	1,448	150	11.6%
XTANDI	731	795	64	8.7%
PADCEV	33	90	57	170.6%
VEOZA	-	7	7	-
XOSPATA	47	55	8	17.2%
EVRENZO	5	10	5	102.0%
BETMIGA	158	183	24	15.4%
PROGRAF	234	226	-8	-3.4%

FY23 Full Year
2,651
1,477
94
1
97
13
327
471

Initial Forecasts	Revised Forecasts	Change from FY23
FY24 Full Year	FY24 Full Year	Change (%)
2,822	2,931	10.5%
1,525	1,614	9.3%
182	200	113.1%
13	20	-
109	112	15.3%
17	20	61.1%
368	374	14.4%
449	450	-4.5%

- Established Markets: Europe, Canada, etc.

(4) China

Unit: B¥

	FY23 APR. - SEP.	FY24 APR. - SEP.	Change	Change (%)
Revenue	36.4	37.7	1.3	3.6%
XTANDI	7.9	6.9	-1.0	-13.1%
PADCEV	-	0.2	0.2	-
XOSPATA	1.2	3.0	1.8	154.6%
BETMIGA	0.7	0.9	0.1	18.5%
PROGRAF	21.7	21.9	0.2	0.8%

FY23 Full Year
70.6
12.2
0.1
3.1
1.6
43.5

Initial Forecasts	Revised Forecasts	Change from FY23
FY24 Full Year	FY24 Full Year	Change (%)
70.5	75.5	6.9%
14.7	15.1	24.3%
0.7	3.8	-
3.5	4.3	39.1%
1.2	1.4	-10.5%
41.3	42.0	-3.3%

- China: China, Hong Kong

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

- XTANDI: From Q1/FY2024, the distribution model was changed. Due to the timing of shipments following this change, the figures decreased year on year. (Direct comparison showed an increase year on year)

(5) International Markets

Unit: B¥

	FY23 APR. - SEP.	FY24 APR. - SEP.	Change	Change (%)
Revenue	83.2	100.0	16.8	20.2%
XTANDI	30.8	39.2	8.4	27.2%
PADCEV	0.2	2.1	1.9	762.3%
XOSPATA	1.7	2.5	0.8	49.0%
EVRENZO	0.2	0.2	-0.0	-9.0%
BETMIGA	8.0	9.6	1.6	20.2%
PROGRAF	22.1	27.3	5.2	23.3%
HARNAL	10.2	11.0	0.8	7.6%

FY23 Full Year
177.0
70.3
1.3
3.9
0.5
16.6
46.3
20.8

Initial Forecasts	Revised Forecasts	Change from FY23
FY24 Full Year	FY24 Full Year	Change (%)
187.0	190.3	7.5%
77.9	79.7	13.4%
3.4	4.6	245.2%
5.5	5.2	33.3%
0.3	0.3	-23.6%
17.4	17.9	7.6%
45.5	46.9	1.2%
20.9	21.2	2.1%

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

9. Consolidated statements of financial position

Unit: B¥

	FY23 End	FY24 Q2 End	Change
Assets	3,569.6	3,462.2	-107.4
Non-current assets	2,374.9	2,259.2	-115.6
Property, plant and equipment	293.7	315.3	21.6
Goodwill	418.7	399.4	-19.3
Intangible assets	1,453.8	1,321.6	-132.2
Trade and other receivables	20.0	20.1	0.0
Investments accounted for using equity method	15.7	18.1	2.5
Deferred tax assets	45.6	53.2	7.6
Other financial assets	108.7	104.9	-3.8
Other non-current assets	18.6	26.6	8.0
Current assets	1,194.7	1,203.0	8.3
Inventories	248.7	260.2	11.5
Trade and other receivables	535.0	558.3	23.3
Income tax receivable	13.1	12.6	-0.4
Other financial assets	28.8	36.3	7.5
Other current assets	32.2	42.6	10.4
Cash and cash equivalents	335.7	293.0	-42.7
Assets held for sale	1.2	-	-1.2

Unit: B¥

	FY23 End	FY24 Q2 End	Change
Equity and Liabilities	3,569.6	3,462.2	-107.4
Equity	1,596.0	1,529.8	-66.1
Equity attributable to owners of the parent	1,596.0	1,529.8	-66.1
Share capital	103.0	103.0	-
Capital surplus	184.1	183.5	-0.5
Treasury shares	-33.8	-38.0	-4.2
Retained earnings	809.4	817.6	8.2
Other components of equity	533.3	463.7	-69.6
Liabilities	1,973.6	1,932.4	-41.2
Non-current liabilities	687.9	839.0	151.2
Bonds and borrowings	447.7	620.2	172.5
Trade and other payables	2.2	8.3	6.1
Income tax payable	-	1.5	1.5
Deferred tax liabilities	51.3	23.6	-27.7
Retirement benefit liabilities	24.7	23.7	-0.9
Provisions	7.4	4.5	-2.8
Other financial liabilities	105.6	110.4	4.8
Other non-current liabilities	49.0	46.7	-2.3
Current liabilities	1,285.7	1,093.4	-192.4
Bonds and borrowings	472.3	307.3	-165.0
Trade and other payables	185.2	161.2	-24.0
Income tax payable	38.5	36.0	-2.5
Provisions	15.7	14.2	-1.5
Other financial liabilities	97.6	86.2	-11.4
Other current liabilities	476.5	488.5	12.0

10. Employees

Number of employees

	FY23 Q2 End	FY24 Q2 End
Total	14,698	13,514

FY23 Q4 End
14,754

11. Shareholders

	FY23 Q2 End	FY24 Q2 End
Banks	37.7%	36.5%
Securities	6.2%	6.5%
Other companies	3.1%	3.3%
Foreign companies	44.0%	40.0%
Individuals and others	8.9%	13.6%
Treasury Stock*	0.0%	0.0%

* Treasury Stock does not include shares owned by the executive compensation BIP (Board Incentive Plan) trust and ESOP (Employee Stock Ownership Plan) trust.

[Three months ended September 30, 2024]

1. Consolidated Results (Full Basis)

Unit: B¥

	FY24			
	APR.-JUN.	Change	JUL.-SEP.	Change
	(Quarterly)	(%)	(Quarterly)	(%)
Revenue	473.1	26.2%	462.5	17.9%
Cost of sales	91.1	32.2%	82.7	11.1%
Ratio to Revenue	19.3%		17.9%	
Gross profit	382.0	24.8%	379.8	19.5%
SG&A expenses	206.9	23.0%	199.5	11.3%
Ratio to Revenue	43.7%		43.1%	
XTANDI co-promotion fee in the United States	61.6	38.2%	64.4	32.9%
SG&A excl. the above	145.3	17.5%	135.1	3.3%
Ratio to Revenue	30.7%		29.2%	
R&D expenses	86.8	34.4%	85.5	10.5%
Ratio to Revenue	18.4%		18.5%	
Amortisation of intangible assets	35.0	285.9%	34.2	38.8%
Gain on divestiture of intangible assets	0.9	-	-	-
Share of profit (loss) of investments accounted for using equity method	1.9	181.2%	-0.5	-
Other income	4.9	25.2%	-0.4	-
Fair value remeasurements on contingent consideration	2.0	-22.6%	0.6	690.9%
Other expenses	10.4	-55.0%	16.6	-57.3%
Impairment losses	0.6	-94.1%	0.0	-98.7%
Restructuring costs	2.6	89.9%	5.3	268.3%
Net foreign exchange losses	-	-	12.2	-
Fair value remeasurements on contingent consideration	5.7	-43.7%	-5.1	-
Operating profit	50.7	10.6%	43.1	359.8%
Ratio to Revenue	10.7%		9.3%	
Finance income	4.3	14.7%	0.5	-77.2%
Finance expenses	4.5	65.2%	5.0	122.5%
Profit before tax	50.5	7.8%	38.5	307.1%
Ratio to Revenue	10.7%		8.3%	
Income tax expense	12.9	-6.0%	2.6	-61.1%
Profit	37.6	13.5%	35.9	-
Ratio to Revenue	7.9%		7.8%	
Comprehensive income	149.5	11.1%	-148.1	-

2. Consolidated Results (Core Basis)

Unit: B¥

		FY24			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		473.1	26.2%	462.5	17.9%
Cost of sales		91.1	32.2%	82.7	11.1%
	Ratio to Revenue	19.3%		17.9%	
Gross profit		382.0	24.8%	379.8	19.5%
SG&A expenses		206.9	23.0%	199.5	11.3%
	Ratio to Revenue	43.7%		43.1%	
XTANDI co-promotion fee in the United States		61.6	38.2%	64.4	32.9%
SG&A excl. the above		145.3	17.5%	135.1	3.3%
	Ratio to Revenue	30.7%		29.2%	
R&D expenses		86.8	34.4%	85.5	10.5%
	Ratio to Revenue	18.4%		18.5%	
Operating profit		88.3	20.5%	94.8	55.1%
	Ratio to Revenue	18.7%		20.5%	
Finance income		4.3	14.7%	0.5	-77.2%
Finance expenses		4.5	65.2%	5.0	122.5%
Profit before tax		88.1	18.6%	90.3	47.5%
	Ratio to Revenue	18.6%		19.5%	
Income tax expense		21.0	27.8%	16.7	69.1%
Profit		67.2	15.9%	73.6	43.3%
	Ratio to Revenue	14.2%		15.9%	

3. Revenue by Region

Unit: B¥

		FY24			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		473.1	26.2%	462.5	17.9%
	Japan	66.7	-2.4%	66.9	-3.5%
	Ratio to Revenue	14.1%		14.5%	
	United States	212.1	41.4%	207.2	32.2%
	Ratio to Revenue	44.8%		44.8%	
	Established Markets	121.0	25.0%	119.0	16.3%
	Ratio to Revenue	25.6%		25.7%	
	China	18.7	2.4%	19.0	4.8%
Ratio to Revenue	3.9%		4.1%		
International Markets	52.0	33.2%	48.0	8.8%	
Ratio to Revenue	11.0%		10.4%		
Others	2.7	2.9%	2.5	57.5%	
Ratio to Revenue	0.6%		0.5%		

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

4. Investment in Property, Plant and Equipment

Depreciation/Amortisation

Unit: B¥

	FY24			
	APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Investment in Property, Plant and Equipment	13.5	44.8%	15.2	104.5%
Depreciation (PP&E)	10.9	6.9%	11.4	12.1%
Amortisation of Intangible Assets (incl. software, etc.)	39.4	201.7%	38.6	34.1%

- Investment in Property, Plant and Equipment does not include right-of-use asset.

5. Sales of major products

1) Global

Unit: B¥

		FY24			
		APR.-JUN.	Change	JUL.-SEP.	Change
		(Quarterly)	(%)	(Quarterly)	(%)
XTANDI		224.2	28.8%	227.4	21.7%
	Japan	14.9	2.9%	13.9	-3.4%
	United States	119.8	38.0%	125.4	32.7%
	Established Markets	65.7	20.3%	66.0	14.8%
	China	3.0	-9.2%	3.9	-15.8%
	International Markets	20.9	40.3%	18.3	14.9%
PADCEV		38.4	152.3%	37.0	111.6%
	Japan	2.5	13.1%	2.4	13.2%
	United States	27.2	158.9%	26.0	108.3%
	Established Markets	7.5	211.9%	7.5	175.0%
	China	0.1	-	0.1	-
	International Markets	1.1	-	1.0	521.5%
IZERVAY		12.7	-	15.4	-
	United States	12.7	-	15.4	-
VEOZAH		6.6	972.0%	8.2	-
	United States	6.1	895.9%	7.4	-
	Established Markets	0.4	-	0.7	-
VYLOY		0.3	-	0.9	-
	Japan	0.3	-	0.9	-
XOSPATA		17.3	32.8%	17.5	31.8%
	Japan	1.3	5.8%	1.1	6.9%
	United States	8.9	25.9%	8.9	28.4%
	Established Markets	4.6	39.5%	4.5	15.7%
	China	1.4	162.0%	1.6	148.7%
	International Markets	1.1	23.8%	1.4	77.1%
BETANIS/MYRBETRIQ/BETMIGA		46.1	-6.4%	31.5	-32.5%
	Japan	6.6	-9.6%	5.9	-13.7%
	United States	18.7	-28.2%	5.6	-75.2%
	Established Markets	15.4	34.1%	14.9	16.2%
	China	0.4	8.2%	0.4	31.6%
	International Markets	4.9	24.5%	4.7	15.9%
PROGRAF		53.9	9.8%	50.1	-1.8%
	Japan	6.4	-20.7%	5.7	-22.5%
	United States	2.7	14.6%	2.6	-1.7%
	Established Markets	19.2	8.0%	18.3	0.8%
	China	11.2	-2.3%	10.7	4.2%
	International Markets	14.4	52.8%	13.0	1.6%

- Established Markets: Europe, Canada, etc.

- China: China, Hong Kong

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

- XTANDI (China): From Q1/FY2024, the distribution model was changed. Due to the timing of shipments following this change, the figures decreased year on year. (Direct comparison showed an increase year on year)

- PADCEV (United States): Co-promotion revenue from Pfizer

- VEOZAH: Approved as "VEOZA" in ex-US

2) Revenue by region

(1) Japan

Unit: B¥

		FY24			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		66.7	-2.4%	66.9	-3.5%
	XTANDI	14.9	2.9%	13.9	-3.4%
	PADCEV	2.5	13.1%	2.4	13.2%
	VYLOY	0.3	-	0.9	-
	XOSPATA	1.3	5.8%	1.1	6.9%
	EVRENZO	0.5	-16.3%	0.4	-22.2%
	BETANIS	6.6	-9.6%	5.9	-13.7%
	PROGRAF (Including GRACEPTOR)	6.4	-20.7%	5.7	-22.5%
	SUGLAT [Family]	7.0	-4.8%	6.5	-7.9%
	SUJANU	2.8	-4.6%	2.6	-4.9%
	BLINCYTO	3.2	34.1%	3.3	25.8%
	EVENITY	13.8	19.6%	13.7	14.3%
	CIMZIA	2.5	-2.5%	2.4	-10.1%

(2) United States

Unit: M\$

		FY24			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		1,360	24.6%	1,390	28.2%
	XTANDI	768	21.6%	840	28.5%
	PADCEV	174	128.1%	174	101.5%
	IZERVAY	82	-	103	-
	VEOZAH	39	777.6%	50	998.0%
	XOSPATA	57	10.9%	59	24.8%
	MYRBETRIQ	120	-36.7%	40	-74.6%
	PROGRAF	17	1.0%	17	-4.6%
	CRESEMBA	70	12.4%	77	23.7%

(3) Established Markets

Unit: M€

		FY24			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		721	11.4%	727	11.7%
	XTANDI	391	7.2%	403	10.2%
	PADCEV	45	178.0%	46	163.7%
	VEOZA	3	-	4	-
	XOSPATA	27	24.3%	28	10.9%
	EVRENZO	5	119.2%	5	87.3%
	BETMIGA	92	19.5%	91	11.5%
	PROGRAF	115	-3.7%	112	-3.0%

- Established Markets: Europe, Canada, etc.

(4) China

Unit: B¥

		FY24			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		18.7	2.4%	19.0	4.8%
	XTANDI	3.0	-9.2%	3.9	-15.8%
	PADCEV	0.1	-	0.1	-
	XOSPATA	1.4	162.0%	1.6	148.7%
	BETMIGA	0.4	8.2%	0.4	31.6%
	PROGRAF	11.2	-2.3%	10.7	4.2%

- China: China, Hong Kong

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

- XTANDI: From Q1/FY2024, the distribution model was changed. Due to the timing of shipments following this change, the figures decreased year on year. (Direct comparison showed an increase year on year)

(5) International Markets

Unit: B¥

		FY24			
		APR.-JUN. (Quarterly)	Change (%)	JUL.-SEP. (Quarterly)	Change (%)
Revenue		52.0	33.2%	48.0	8.8%
	XTANDI	20.9	40.3%	18.3	14.9%
	PADCEV	1.1	-	1.0	521.5%
	XOSPATA	1.1	23.8%	1.4	77.1%
	EVRENZO	0.1	100.3%	0.1	-47.9%
	BETMIGA	4.9	24.5%	4.7	15.9%
	PROGRAF	14.4	52.8%	13.0	1.6%
	HARNAL	5.3	9.1%	5.6	6.2%

- International Markets: Latin America, Middle East, Africa, South East Asia, South Asia, Russia, Korea, Taiwan, Australia, Export sales, etc.

- From Q1/FY2024, the commercial segment of Taiwan was changed from China to International Markets. All figures above reflect this change.

R&D Pipeline

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

As of Oct 2024

Underlined items indicate changes from the previous announcement in Aug 2024.

Strategic Brands (1/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
enfortumab vedotin ASG-22ME (PADCEV)	Antibody-drug conjugate (ADC)	Nectin-4 targeted ADC	Metastatic urothelial cancer, platinum-containing chemotherapy and PD-1/L1 inhibitor pretreated	China <u>Approved (Aug 2024)</u>	In-house [Co-development with Pfizer]	
			Metastatic urothelial cancer, previously untreated (first line; combo with pembrolizumab)	Europe <u>Approved (Aug 2024)</u> Japan <u>Approved (Sep 2024)</u> China <u>Filed (Mar 2024)</u>		
			Muscle-invasive bladder cancer (combo with pembrolizumab)	P-III		
			Other solid tumors	P-II		
			Non-muscle-invasive bladder cancer	P-I		
gilteritinib ASP2215 (XOSPATA)	Small molecule	FLT3 inhibitor	Post-chemotherapy maintenance acute myeloid leukemia	P-III	In-house	
			Post-hematopoietic stem cell transplant maintenance acute myeloid leukemia	P-III		
			Newly diagnosed acute myeloid leukemia with high intensity induction of chemotherapy	P-III		
			Newly diagnosed acute myeloid leukemia with low intensity induction of chemotherapy	P-I		
			Acute myeloid leukemia in pediatric patients	P-III		

Strategic Brands (2/2)

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
zolbetuximab IMAB362 (VYLOY)	Antibody	Anti-Claudin 18.2 monoclonal antibody	Gastric and gastroesophageal junction adenocarcinoma (combo with chemotherapy)	US <u>Approved (Oct 2024)</u> Europe <u>Approved (Sep 2024)</u> China <u>Filed (Jul 2023)</u>	In-house (Ganymed)	
			Gastric and gastroesophageal junction adenocarcinoma (combo with checkpoint inhibitor and chemotherapy)	P-III		
			Pancreatic adenocarcinoma	P-II		
fezolinetant ESN364 (VEOZAH***)	Small molecule	NK3 receptor antagonist	Vasomotor symptoms due to menopause	China P-III Japan P-III	In-house (Ogeda)	
			Induced vasomotor symptoms in breast cancer patients on adjuvant endocrine therapy	P-III		
avacincaptad pegol (IZERVAY)	Pegylated RNA aptamer	Complement C5 inhibitor	Geographic atrophy secondary to age-related macular degeneration	Europe <u>Withdrawn (Oct 2024)</u>	In-house (Iveric Bio)	
			Stargardt disease	P-II		

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

*** Approved as "VEOZA" in ex-US.

Updates from the previous announcement (Aug 2024):

enzalutamide: Removed the description of the approval in China for metastatic castration-sensitive prostate cancer in Jun 2024.

enfortumab vedotin: Approved in China in Aug 2024 for metastatic urothelial cancer, platinum-containing chemotherapy and PD-1/L1 inhibitor pretreated. Approved in Europe in Aug 2024 for the first-line treatment of unresectable or metastatic urothelial cancer (eligible for platinum-containing chemotherapy). Approved in Japan in Sep 2024 for the first-line treatment of radically unresectable urothelial carcinoma.

zolbetuximab: Approved in US in Oct 2024 and in Europe in Sep 2024 for the first-line treatment of locally advanced unresectable or metastatic HER2-negative, claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma.

avacincaptad pegol: Withdrawn the application in Europe in Oct 2024 for geographic atrophy secondary to age-related macular degeneration.

Programs with Focus Area approach (1/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensor **	Remarks
Immuno-oncology	ASP1570	Small molecule	DGK ζ inhibitor	Cancer	P-I	In-house	
	ASP2138	Antibody	Anti-Claudin 18.2 and anti-CD3 bispecific antibody	Gastric and gastroesophageal junction adenocarcinoma, pancreatic adenocarcinoma	P-I	Xencor [Discovered through collaborative research]	
	ASP1002	Antibody	Anti-Claudin 4 and anti-CD137 bispecific antibody	Cancer	P-I	In-house	
	ASP1012	Oncolytic virus	Oncolytic virus encoding leptin-IL-2	Cancer	P-I	KaliVir	
	ASP2802	Cell therapy	CD20 autologous convertible CAR-T	B-cell lymphoma	P-I	In-house (Xyphos Biosciences)	
Targeted Protein Degradation	ASP3082	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	
	ASP4396	Small molecule	KRAS G12D degrader	Cancer	P-I	In-house	

Programs with Focus Area approach (2/2)

Primary Focus	Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
Genetic regulation	resamirigene bilparvovec AT132	Gene therapy (AAV-based gene therapy)	MTM1 gene replacement to express myotubularin	X-linked myotubular myopathy	P-II	In-house (Audentes Therapeutics)	
	zocaglusagene nuzaparvovec AT845	Gene therapy (AAV-based gene therapy)	GAA gene replacement to express GAA enzyme	Pompe disease	P-I	In-house (Audentes Therapeutics)	
	ASP2016	Gene therapy (AAV-based gene therapy)	FXN gene replacement to express frataxin	Cardiomyopathy associated with Friedreich ataxia	P-I	In-house (Audentes Therapeutics)	
Blindness and Regeneration	ASP7317	Cell therapy	Retinal pigment epithelial cells	Geographic atrophy secondary to age-related macular degeneration	P-I	In-house (Ocata Therapeutics)	
Immune Homeostasis ***	ASP5502	Small molecule	STING inhibitor	Primary Sjogren's syndrome	P-I	In-house	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

*** Primary Focus Candidate.

Others

Generic name Code No. (Brand name)	Modality / Technology	Classification	Target disease	Phase *	Licensors **	Remarks
mirabegron YM178	Small molecule	β_3 receptor agonist	Neurogenic detrusor overactivity in pediatric patients (aged 3 to less than 18 years)	Europe <u>Approved (Aug 2024)</u>	In-house	
			Neurogenic detrusor overactivity in pediatric patients (aged 6 months to less than 3 years)	Europe P-III		
peficitinib ASP015K	Small molecule	JAK inhibitor	Rheumatoid arthritis	China <u>Approved (Jul 2024)</u>	In-house	
roxadustat ASP1517/FG-4592	Small molecule	HIF-PH inhibitor	Anemia associated with chronic kidney disease in pediatric patients	Europe P-III	FibroGen	Astellas has rights in Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa.
abiraterone decanoate ASP5541 (PRL-02)	Small molecule	CYP17 lyase inhibitor	Prostate cancer	P-I	In-house (Propella Therapeutics)	

* Compounds are developed globally unless noted. The list shows the most advanced stage if the stages are different depending on the region. The list specifies the area if the compound is developed in limited areas.

** Compounds with "In-house" in this column include ones discovered by collaborative research.

Updates from the previous announcement (Aug 2024):

mirabegron: Approved in Europe in Aug 2024 for neurogenic detrusor overactivity in pediatric patients (aged 3 to less than 18 years).

peficitinib: Approved in China in Jul 2024 for rheumatoid arthritis.

Rx+ Program

As of Oct 2024

Underlined items indicate changes from the previous announcement in Aug 2024.

Category	Program	Concept	Status*	Partner	Remarks
Digital health Other services	BlueStar	Digital therapeutics for adults with diabetes	Pivotal study (Japan)	Welldoc Roche Diabetes Care Japan	
	<u>DIGITIVA</u> <u>Z1608</u>	Non-invasive digital health solution for heart failure management	<u>FDA listed (Sep 2024)</u> <u>Under preparation for pilot launch</u>	Welldoc Eko	
Drug-device combination	<u>pudexacianinium chloride</u> <u>ASP5354</u>	Intraoperative ureter visualization for use in patients undergoing minimally invasive and open abdominopelvic surgeries	P-III	Stryker	
<u>Implantable medical device</u>	<u>Implantable bladder device</u>	<u>Implantable device for underactive bladder</u>	<u>FDA approved to enter into early feasibility study</u>	<u>(iota Biosciences)</u>	

* The list shows the most advanced stage if the stages are different depending on the region.

Updates from the previous announcement (Aug 2024):

DIGITIVA: Listed with US FDA. Initiated preparation for pilot launch.

Implantable bladder device: Approved by FDA to enter into early feasibility study in US.